S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
NASDAQ:MNPR

Monopar Therapeutics Price Target, Predictions & Analyst Ratings

$2.20
+0.23 (+11.39%)
(As of 05/18/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.20
$2.30
50-Day Range
$1.85
$2.94
52-Week Range
$1.70
$6.98
Volume
13,721 shs
Average Volume
10,518 shs
Market Capitalization
$27.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.77

Monopar Therapeutics (NASDAQ:MNPR) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Buy
Based on 3 Analyst Ratings

Analyst Price Target Consensus

$9.00
309.09% Upside

High PT$9.00
Average PT$9.00
Low PT$9.00
TypeCurrent
5/18/21 to 5/18/22
1 Month Ago
4/18/21 to 4/18/22
3 Months Ago
2/17/21 to 2/17/22
1 Year Ago
5/18/20 to 5/18/21
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$9.00$9.00$9.00$30.00
Price Target Upside309.09% Upside242.21% Upside87.50% Upside418.36% Upside
Get Monopar Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Monopar Therapeutics (NASDAQ:MNPR) vs. Its Competitors

TypeMonopar TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.53
Consensus RatingBuyBuyBuy
Price Target Upside355.70% Upside449.50% Upside27.49% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
30
71.43%
Underperform Votes
12
28.57%
Avg. Outperform Votes
172
67.19%
Avg. Underperform Votes
84
32.81%
Avg. Outperform Votes
839
69.34%
Avg. Underperform Votes
371
30.66%

Monopar Therapeutics (NASDAQ:MNPR) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/25/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sean Lee CFA
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$9.00+242.20%
3/24/2022Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Piros
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
5/25/2021Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Raja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
9/24/2020Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$11.00+121.11%
(Data available from 5/18/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Monopar Therapeutics (NASDAQ:MNPR) Analyst Ratings Frequently Asked Questions

What is Monopar Therapeutics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Monopar Therapeutics stock is Buy based on the current 3 buy ratings for MNPR. The average twelve-month price target for Monopar Therapeutics is $9.00 with a high price target of $9.00 and a low price target of $9.00. Learn more on MNPR's analyst rating history.

Do Wall Street analysts like Monopar Therapeutics more than its competitors?

Analysts like Monopar Therapeutics stock more than the stock of other Medical companies. The consensus rating score for Monopar Therapeutics is 3.00 while the average consensus rating score for medical companies is 2.72. Learn more on how MNPR compares to other companies.

Do MarketBeat users like Monopar Therapeutics more than its competitors?

MarketBeat users like Monopar Therapeutics stock more than the stock of other Medical companies. 71.43% of MarketBeat users gave Monopar Therapeutics an outperform vote while medical companies recieve an average of 67.19% outperform votes by MarketBeat users.

Does Monopar Therapeutics's stock price have much upside?

According to analysts, Monopar Therapeutics's stock has a predicted upside of 242.21% based on their 12-month price targets.

What analysts cover Monopar Therapeutics?

Monopar Therapeutics has been rated by HC Wainwright, and Roth Capital in the past 90 days.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.